<DOC>
	<DOC>NCT00599924</DOC>
	<brief_summary>This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors, including colorectal cancer.</brief_summary>
	<brief_title>Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors</brief_title>
	<detailed_description>Study Design: Treatment, Single Group Assignment (7 cohorts), Open Label, Non-Randomized, Safety Study.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Advanced solid tumor malignancy (during expansion at the maximum tolerated dose, entry will be limited to patients wtih adenocarcinoma of the colon or rectum) Eastern Cooperative Oncology Group (ECOG) 0 or 1 Prior treatment with more than 6 cycles of traditional alkylating agentbased chemotherapy regimens Prior treatment with more than 2 cycles of carboplatingbased chemotherapy regimens For colorectal cancer patients in the expanded cohorts, prior treatment with more than 2 systemic chemotherapy regimens in the metastatic setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>advanced solid tumors,</keyword>
	<keyword>colorectal cancer,</keyword>
	<keyword>sunitinib (SUTENT),</keyword>
	<keyword>FOLFOX</keyword>
</DOC>